WO1995019343A1 - Derive de l'indole - Google Patents
Derive de l'indole Download PDFInfo
- Publication number
- WO1995019343A1 WO1995019343A1 PCT/JP1995/000019 JP9500019W WO9519343A1 WO 1995019343 A1 WO1995019343 A1 WO 1995019343A1 JP 9500019 W JP9500019 W JP 9500019W WO 9519343 A1 WO9519343 A1 WO 9519343A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- lower alkyl
- substituted
- hydrogen
- different
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Definitions
- the present invention relates to an indole derivative useful as a therapeutic agent for osteoporosis.
- Japanese Patent Application Laid-Open No. 3-215461 discloses that a triphenylmethane derivative having a substituent such as carbamoyl is useful as a therapeutic agent for osteoporosis.
- Japanese Patent Application Laid-Open No. 4-216165 discloses that an indole derivative having a phenyl group is useful as a therapeutic agent for osteoporosis.
- the present invention provides a compound represented by the general formula (I):
- R 1 and R 2 are the same or different and are hydrogen, lower alkyl
- R 6 represents hydrogen or lower alkyl, and n represents an integer of 1 to 6)
- R 7 and R 8 are the same or different and each represents hydrogen or lower alkyl, or R 7 and R 8 together form a substituted or unsubstituted group formed together with an adjacent nitrogen atom.
- R 9 and R 1 Q are the same or different, if substituted Kuwahi hydrogen or lower alkyl tables carded and R 9 and R 1 Q is formed together such connection, together with the adjacent nitrogen atom
- p represents an integer of 2 to 6
- R 4 and R 5 are the same or different and are hydrogen, lower alkyl, alicyclic alkyl, substituted or unsubstituted Represents a substituted aryl or a substituted or unsubstituted heterocyclic group, or a substituted or unsubstituted alicyclic heterocyclic group formed together with an adjacent nitrogen atom when R 4 and R 5 are taken together.
- a pharmacologically acceptable salt thereof thereof.
- compound (I) the compound represented by the general formula (I).
- compound (I) the compound represented by the general formula (I).
- the lower alkyl is a straight-chain or branched-chain having 1 to 8 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl. Butyl, pentyl, neopentyl, hexyl, heptyl, octyl and the like; alicyclic alkyl having 3 to 8 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, etc.
- aryl examples include phenyl or naphthyl
- examples of the alicyclic heterocyclic group include, for example, pyrrolidinyl, imidazolidinyl, birazolidinyl, piperidyl, piperidino, piperazinyl, homopiperazinyl, morpholino, thiomorpholino, and the like.
- Substituents in the substituted alicyclic heterocyclic group, substituted heterocyclic group and substituted aryl are the same or different and have 1 to 3 substituents, for example, lower alkyl, hydroxy, lower alkoxy, lower alkylthio, aralkyl Carboxy, lower alkoxycarbonyl, lower alkanoyl, aroyl, halogen, nitro, amino, mono- or di-lower alkylamino, trifluoromethyl, substituted or unsubstituted phenyl, pyridyl, pyrimidinyl and the like.
- the lower alkyl portion of lower alkyl and lower alkoxy, lower alkylthio, lower alkoxycarbonyl, mono- or di-lower alkylamino has the same meaning as the above lower alkyl.
- Aralkyl, carbon number? 13 to, for example, benzyl, phenethyl, benzhydryl, naphthylmethyl and the like, and the lower alkanoyl having 1 to 7 carbon atoms, for example, formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, vivaloyl, hexanoyl And heptanyl.
- the aryl portion of the alloy is synonymous with the aryl.
- Halogen means fluorine, chlorine, bromine and iodine atoms.
- the substituents of the substituted phenyl may be the same or different and have 1 to 3 substituents, for example, lower alkyl, hydroxy, lower alkoxy, lower alkylthio, aralkyl, carboxy, lower alkoxycarbonyl, lower alkanoyl, aroyl, halogeno, nitro , Amino, mono- or di-lower alkylamino, trifluoromethyl, etc .; lower alkyl, lower alkoxy, lower alkylthio, aralkyl, lower alkoxycarbonyl, lower alkanol, aroyl, halogen, and mono- or di-lower alkylamino are as defined above. It is.
- Pharmaceutically acceptable salts of compound (I) include, for example, inorganic salts such as hydrochloride, sulfate, nitrate, phosphate, acetate, maleate, fumarate, tartrate, quencher Organic salts such as acid salts, lactates, dalioxylates, aspartates, methanesulfonates, ethanesulfonates, benzenesulfonates, metal salts such as sodium salts, potassium salts, calcium salts, etc., ammonium salts, Examples thereof include amine addition salts such as tetramethylammonium salt and morpholine salt.
- inorganic salts such as hydrochloride, sulfate, nitrate, phosphate, acetate, maleate, fumarate, tartrate, quencher Organic salts such as acid salts, lactates, dalioxylates, aspartates, methanesulfonates, ethanesulfonates,
- Compound (I) is prepared by converting compound (II) with compound (III) in the presence of an acid catalyst such as 0.1 to 1 equivalent of boron trifluoride etherate, paratoluenesulfonic acid, trifluorosulfuric acid, methylene chloride, It can be obtained by reacting in a solvent such as black form, ether, tetrahydrofuran or the like at a temperature of from 20 ° C. to the boiling point of the solvent for 0.5 to 24 hours.
- an acid catalyst such as 0.1 to 1 equivalent of boron trifluoride etherate, paratoluenesulfonic acid, trifluorosulfuric acid, methylene chloride
- Compound (Ib) in which R 1 , R 2 and R 3 are all groups other than hydrogen in compound (I) is a compound (I a) in which R 1 and R 2 are groups other than hydrogen and R 3 is hydrogen. ) It can also be produced according to the following reaction steps.
- R la , R 2a and R 3a each represent a group other than hydrogen in the definition of R 1 , R 2 and R 3 , X represents chlorine, bromine or iodine, and R 4 and R 5 Is synonymous with)
- Compound (Ib) is obtained by combining compound (Ia) with an alkyl halide or halogenated alkyl halide.
- Minoalkyl is dissolved in a solvent such as methanol, ethanol or other lower alcohols, NN-dimethylformamide, dimethyl sulfoxide, tetrahydrofuran, etc. in the presence of a base such as sodium hydride or potassium tert-butoxide at 0 C to the boiling point of the solvent. , 0.5 for 24 hours.
- the compound (Iba) is produced from the compound (la) according to the following reaction process.
- Compound (IV) is obtained by converting compound (la) with an ", ⁇ -dialkyl halide in the presence of a base such as sodium hydride or potassium tert-butoxide, a lower alcohol such as methanol or ethanol, ⁇ , ⁇ -dimethylformamide.
- Compound (lba) can be obtained by reacting in a solvent such as dimethylsulfoxide, tetrahydrofuran, etc. at 0 ° C. to the boiling point of the solvent for 0.5 to 24 hours.
- Compound (Id) in which both R 1 and R 2 are hydrogen in compound (I) may be produced from compound (Ic) in which R 1 and R 2 are both methoxymethyl according to the following reaction steps. it can.
- Compound (Id) is prepared by converting compound (Ic) to a lower alcohol such as methanol or ethanol, N, N-dimethylformamide, dimethylsulfoxide in the presence of an acid catalyst such as hydrochloric acid, sulfuric acid, or paratoluenesulfonic acid. 0.5 to 24 hours treatment in a solvent such as tetrahydrofuran or water or a mixed solvent thereof at room temperature to the boiling point of the solvent Can be obtained.
- a solvent such as tetrahydrofuran or water or a mixed solvent thereof at room temperature to the boiling point of the solvent Can be obtained.
- compound (I) can also be produced from compound (V) according to the following reaction steps.
- Compound (I) is obtained by converting compound (V) with ammonia, a primary amine or a secondary amine, to dicyclohexylcarbodiimide, 11- (3-dimethylaminopropyl) -13-ethylcarbodiimide. It can be obtained by reacting for 1 to 24 hours at room temperature to the boiling point of the solvent in a solvent such as methylene chloride, chloroform and tetrahydrofuran in the presence of a condensing agent such as a hydrochloride.
- a solvent such as methylene chloride, chloroform and tetrahydrofuran
- compound (II) can be obtained by the method described in Tetrahedron Lett., _2 ⁇ _5651 (1987) or according to the method. Also, the compound (II) can be obtained by the method described in Tetrahedron Lett., _2 ⁇ _5651 (1987) or according to the method. Also, the compound (II) can be obtained by the method described in Tetrahedron Lett., _2 ⁇ _5651 (1987) or according to the method. Also, the compound (II) can be obtained by the method described in Tetrahedron Lett., _2 ⁇ _5651 (1987) or according to the method. Also, the compound (II) can be obtained by the method described in Tetrahedron Lett., _2 ⁇ _5651 (1987) or according to the method. Also, the compound (II) can be obtained by the method described in Tetrahedron Lett., _2 ⁇ _5651 (1987) or according to the method. Also, the compound (
- (III) can be obtained by the method described in J. Am. Chem. Soc., 423 (1945) or J. Med. Chem., 32, 1681 (1989) or according to the method.
- Compound (Va) in which R 1 , R 2 and R 3 are all groups other than hydrogen in compound (V) can be produced from compound (IIa) and compound (1) according to the following reaction steps.
- R 11 represents lower alkyl
- X, R la , R 2a and R 3a have the same meaning as described above.
- Compound (2) is obtained from compound (II) and compound (III) from compound (IIa) and compound (1) obtained according to the method described in Chei Pharm. Bull., 21, 1481 (1973) or a method analogous thereto. It can be obtained according to the method for producing compound (I).
- Compound (3) can be obtained from compound (2) according to the method for producing compound (Ib) from compound (Ia).
- the compound (v a ) is converted from the compound (3) under a normal hydrolysis condition, for example, in the presence of a base such as lithium hydroxide, sodium hydroxide or potassium hydroxide, a lower alcohol such as methanol or ethanol, In a solvent such as tetrahydrofuran, N, N-dimethylformamide, dimethylsulfoxide, etc., add water as needed, and then at room temperature to the boiling point of the solvent for 0.5 to 24 hours It can be obtained by reacting.
- a base such as lithium hydroxide, sodium hydroxide or potassium hydroxide
- a lower alcohol such as methanol or ethanol
- a solvent such as tetrahydrofuran, N, N-dimethylformamide, dimethylsulfoxide, etc.
- Compound (Vb), in which R 1 and R 2 are groups other than hydrogen and R 3 is hydrogen in compound (V), is a method of obtaining compound (3) from compound (2) to obtain compound (V). It can be produced by hydrolyzing the ester portion according to the method.
- Intermediates and target compounds in the above production methods can be purified and isolated by purification methods commonly used in organic synthetic chemistry, such as filtration, extraction, washing, drying, concentration, recrystallization, and various types of chromatography. it can.
- the intermediate can be subjected to the next reaction without purification.
- the compound (I) can be purified as it is when it can be obtained in the form of a salt, and when it can be obtained in a free form, compound (I)
- a salt may be formed by dissolving or suspending in a suitable solvent and adding an appropriate acid or base to form a salt.
- Compound (I) and its pharmacologically acceptable salts may be present in the form of adducts with water or various solvents. These adducts are also included in the present invention.
- Table 1 shows specific examples of the compound (I) obtained by the above production method.
- Table 10 shows specific examples of the compound (I) obtained by the above production method.
- Test Example 1 Bone resorption inhibitory action
- the calvariae of neonatal dd-line mice at 5-6 days of age are aseptically excised, washed with calcium- and magnesium-free Dulbecco's modified phosphate buffered saline (Gibco Oriental) and split along the central suture line . Heat inactivated half of the calvaria
- the cells were cultured in 1.5 ml of Dulbecco's modified Eagle culture medium (manufactured by Gibco Oriental) containing 15% horse serum and 2.5% fetal calf serum (56 ° C, 20 minutes). Test compounds are dissolved in dimethyl sulfoxide, and the 1 0 1 In addition to the culture medium, the final concentration of 3 X 1 0- 6 M, 1 X 1 0- 5 M, 3 x 1 0- 5 M, also , PTH
- Inhibition rate (%) (CP one C D) Z (CP one (:.) X 1 00
- Test example 2 Suppressing effect of ovariectomy on bone density loss
- Compound (I) or a pharmacologically acceptable salt thereof may be prepared, for example, into tablets, capsules, syrups and other commonly used dosage forms and orally or intramuscularly or intravenously. It can be administered by parenteral administration, such as intravenous injection, infusion, or rectal administration with suppositories.
- parenteral administration such as intravenous injection, infusion, or rectal administration with suppositories.
- the formulation of such oral or parenteral dosage forms is usually For example, various excipients, lubricants, binders, disintegrants, isotonic agents, emulsifiers and the like may be contained.
- Pharmaceutical carriers to be used include, for example, water, distilled water for injection, physiological saline, dalcose, fructose, sucrose, mannite, lactose, starch, cellulose, methylcellulose, sulfoxymethylcellulose, hydroxypropylcellulose, Examples include alginic acid, talc, sodium citrate, calcium carbonate, calcium hydrogen phosphate, magnesium stearate, urea, silicone resins, sorbitan fatty acid esters, and glycerin fatty acid esters.
- the effective dose and frequency of administration of compound (I) or a pharmacologically acceptable salt thereof will vary depending on the dosage form, patient age, body weight, symptoms, etc., but is generally 0.1 to 1 OmgZkg per day. Administer ⁇ 4 divided doses.
- the obtained organic layer was washed with saturated aqueous sodium hydrogen carbonate and saturated brine, dried over magnesium sulfate, and the solvent was distilled off under reduced pressure to obtain a crude product.
- the obtained crude product was crystallized from ethanol to give 15. lg (82% yield) of the title compound.
- the obtained organic layer was washed with brine, dried over magnesium sulfate, and the solvent was distilled off under reduced pressure to obtain 2.9 g of a crude product.
- the target compound was obtained in substantially the same manner as in Example 4, except that the corresponding amine was used instead of propylamine.
- the crystals were collected by filtration from the suspended organic layer, and dried under reduced pressure to obtain 8.8 g (yield: 79%) of the free base of the title compound.
- the crystals were suspended in ethyl acetate (500 ml), and methanesulfonic acid (0.95 ml, 14.6 mmol) was added thereto, followed by stirring at room temperature. The precipitated crystals were collected by filtration and dried under reduced pressure to give 10.9 g (quantitative) of the title compound.
- IRCKBr tablet 1609, 1512, 1481, 1442, 1210 cm one 1
- Example 10 the corresponding compounds 3 to 7 were used in place of the compound 2 to obtain the target compounds in substantially the same manner as in Example 9.
- Example 1 o
- the target compound was obtained in substantially the same manner as in Example 4, except that the corresponding amine was used instead of propylamine.
- the target compound was prepared in substantially the same manner as in Example 2 by using the corresponding substituted ethyl chloride hydrochloride in place of 2-dimethylaminoethyl chloride hydrochloride. Obtained.
- the target compound was obtained in substantially the same manner as in Example 23 or 24 using the compound obtained in Reference Example 4 or 5 and the corresponding amine in place of the aqueous dimethylamine solution.
- Example 23 or 24 using the compound obtained in Reference Example 4 or 5 and the corresponding amine in place of the aqueous dimethylamine solution.
- IRCKBr tablets 3400, 1612, 1513, 1206 cm— 1
- the obtained organic layer was washed with water and a saturated saline solution, dried over magnesium sulfate, and the solvent was distilled off under reduced pressure to obtain 14.4 g of a crude product.
- the obtained crude product was crystallized from ethyl acetate to give 8.9 g (64% yield) of the title compound.
- the reaction solution was neutralized with a saturated aqueous solution of ammonium chloride, water was added, and the mixture was extracted with ethyl acetate.
- the obtained organic layer was washed with water and saturated saline, dried over magnesium sulfate, and the solvent was distilled off under reduced pressure to obtain 6.5 g of a crude product.
- an indole derivative useful as a therapeutic drug for osteoporosis can be provided.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69526332T DE69526332T2 (de) | 1994-01-18 | 1995-01-11 | Indol-derivate |
AU14247/95A AU1424795A (en) | 1994-01-18 | 1995-01-11 | Indole derivative |
EP95905756A EP0741132B1 (en) | 1994-01-18 | 1995-01-11 | Indole derivatives |
AT95905756T ATE215932T1 (de) | 1994-01-18 | 1995-01-11 | Indol-derivate |
US08/676,177 US5891902A (en) | 1994-01-18 | 1996-07-15 | Indole derivatives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6/3334 | 1994-01-18 | ||
JP333494 | 1994-01-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995019343A1 true WO1995019343A1 (fr) | 1995-07-20 |
Family
ID=11554462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1995/000019 WO1995019343A1 (fr) | 1994-01-18 | 1995-01-11 | Derive de l'indole |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0741132B1 (ja) |
AT (1) | ATE215932T1 (ja) |
AU (1) | AU1424795A (ja) |
CA (1) | CA2181374A1 (ja) |
DE (1) | DE69526332T2 (ja) |
WO (1) | WO1995019343A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997003963A1 (fr) * | 1995-07-18 | 1997-02-06 | Kyowa Hakko Kogyo Co., Ltd. | Derives d'indole |
WO1997003965A1 (fr) * | 1995-07-18 | 1997-02-06 | Kyowa Hakko Kogyo Co., Ltd. | Derives d'indole |
WO1997003964A1 (fr) * | 1995-07-18 | 1997-02-06 | Kyowa Hakko Kogyo Co., Ltd. | Derives d'indole |
JP2008231030A (ja) * | 2007-03-20 | 2008-10-02 | Aphoenix Inc | インドール化合物の新規医薬用途及び新規インドール化合物 |
JP2009215223A (ja) * | 2008-03-11 | 2009-09-24 | Nippon Steel Chem Co Ltd | インドール誘導体の製造方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03215461A (ja) * | 1989-04-28 | 1991-09-20 | Kyowa Hakko Kogyo Co Ltd | トリフェニルメタン誘導体 |
JPH04211651A (ja) * | 1990-03-26 | 1992-08-03 | Takeda Chem Ind Ltd | 骨吸収抑制剤およびインドール誘導体 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2038925A1 (en) * | 1990-03-26 | 1991-09-27 | Takashi Sohda | Indole derivatives, their production and use |
-
1995
- 1995-01-11 EP EP95905756A patent/EP0741132B1/en not_active Expired - Lifetime
- 1995-01-11 CA CA002181374A patent/CA2181374A1/en not_active Abandoned
- 1995-01-11 AT AT95905756T patent/ATE215932T1/de not_active IP Right Cessation
- 1995-01-11 AU AU14247/95A patent/AU1424795A/en not_active Abandoned
- 1995-01-11 WO PCT/JP1995/000019 patent/WO1995019343A1/ja active IP Right Grant
- 1995-01-11 DE DE69526332T patent/DE69526332T2/de not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03215461A (ja) * | 1989-04-28 | 1991-09-20 | Kyowa Hakko Kogyo Co Ltd | トリフェニルメタン誘導体 |
JPH04211651A (ja) * | 1990-03-26 | 1992-08-03 | Takeda Chem Ind Ltd | 骨吸収抑制剤およびインドール誘導体 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997003963A1 (fr) * | 1995-07-18 | 1997-02-06 | Kyowa Hakko Kogyo Co., Ltd. | Derives d'indole |
WO1997003965A1 (fr) * | 1995-07-18 | 1997-02-06 | Kyowa Hakko Kogyo Co., Ltd. | Derives d'indole |
WO1997003964A1 (fr) * | 1995-07-18 | 1997-02-06 | Kyowa Hakko Kogyo Co., Ltd. | Derives d'indole |
JP2008231030A (ja) * | 2007-03-20 | 2008-10-02 | Aphoenix Inc | インドール化合物の新規医薬用途及び新規インドール化合物 |
JP2009215223A (ja) * | 2008-03-11 | 2009-09-24 | Nippon Steel Chem Co Ltd | インドール誘導体の製造方法 |
Also Published As
Publication number | Publication date |
---|---|
EP0741132B1 (en) | 2002-04-10 |
CA2181374A1 (en) | 1995-07-20 |
EP0741132A1 (en) | 1996-11-06 |
ATE215932T1 (de) | 2002-04-15 |
AU1424795A (en) | 1995-08-01 |
EP0741132A4 (en) | 1997-09-17 |
DE69526332D1 (de) | 2002-05-16 |
DE69526332T2 (de) | 2002-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2316062T3 (es) | Derivados novedosos de tiofeno como agonistas del receptor de esfingosina-1-fosfato-1. | |
JP3593037B2 (ja) | ピロリジン誘導体ccr−3受容体アンタゴニスト | |
JP3294961B2 (ja) | 新規イミダゾール誘導体及びその製造法 | |
WO2001021615A1 (en) | Benzimidazole derivatives | |
US20090012099A1 (en) | Novel Compounds | |
JPH07505648A (ja) | アザサイクリック化合物 | |
JP2007119502A (ja) | ピペリジン類およびピペラジン類 | |
EP0716650A1 (en) | Indole and indoline derivatives as 5ht1d receptor antagonists | |
US5116995A (en) | Carbazole compounds | |
EP0784055B1 (en) | Pyrimidinylpyrazole derivative | |
JP2007504114A (ja) | 8−(1−ピペラジニル)キノリン誘導体およびcns疾患の治療におけるそれらの使用 | |
US5330986A (en) | Indole-7-carboxamide derivatives | |
RU2418794C2 (ru) | ПРОИЗВОДНЫЕ ИЗОХИНОЛИНА И БЕНЗО[h]ИЗОХИНОЛИНА, ИХ ПОЛУЧЕНИЕ И ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ В КАЧЕСТВЕ АНТАГОНИСТОВ РЕЦЕПТОРА ГИСТАМИНА H3 | |
EP1341783A1 (en) | Isoquinoline derivatives useful in the treatment of cns disorders | |
WO1995019343A1 (fr) | Derive de l'indole | |
AP745A (en) | Heterocyclic compounds and their use in treatment of CNS disorders. | |
RU2175970C2 (ru) | Производные пиперидинилметилоксазолидин-2-она, способ их получения и фармацевтическая композиция на их основе | |
WO1997003965A1 (fr) | Derives d'indole | |
JPH04234359A (ja) | 1−ジフェニルメチルピペラジンの新規誘導体、それらの製法、及びそれらの医薬用途 | |
JPH0733744A (ja) | インダゾール誘導体およびその塩 | |
JP2887492B2 (ja) | 1,2―エタンジオール誘導体およびその塩 | |
KR950011420B1 (ko) | 히드록시인돌 에스테르의 제조방법 | |
WO1997003964A1 (fr) | Derives d'indole | |
JPH11209344A (ja) | 含窒素複素環化合物 | |
WO1997003963A1 (fr) | Derives d'indole |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CN FI HU JP KR NO NZ US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 08676177 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2181374 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995905756 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1995905756 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995905756 Country of ref document: EP |